Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cytokinetics (CYTK) EBITDA: 2009-2024

Historic EBITDA for Cytokinetics (CYTK) over the last 16 years, with Dec 2024 value amounting to -$587.1 million.

  • Cytokinetics' EBITDA fell 98.52% to -$306.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$757.3 million, marking a year-over-year decrease of 32.83%. This contributed to the annual value of -$587.1 million for FY2024, which is 12.33% down from last year.
  • As of FY2024, Cytokinetics' EBITDA stood at -$587.1 million, which was down 12.33% from -$522.7 million recorded in FY2023.
  • Cytokinetics' 5-year EBITDA high stood at -$127.8 million for FY2020, and its period low was -$587.1 million during FY2024.
  • Its 3-year average for EBITDA is -$500.5 million, with a median of -$522.7 million in 2023.
  • Data for Cytokinetics' EBITDA shows a maximum YoY crashed of 81.05% (in 2022) over the last 5 years.
  • Over the past 5 years, Cytokinetics' EBITDA (Yearly) stood at -$127.8 million in 2020, then slumped by 69.25% to -$216.3 million in 2021, then plummeted by 81.05% to -$391.7 million in 2022, then plummeted by 33.44% to -$522.7 million in 2023, then fell by 12.33% to -$587.1 million in 2024.